Stocks · News reference
Lipocine shares are trading higher after the company announced that Health Canada approved TLANDO for testosterone replacement therapy in adult males.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-11-10 AccNo: 0001493152-26-050842 Size: 239 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Lipocine Inc. Reports Third Quarter 2026 Financial Results
Lipocine Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $0.7 million and total revenue of $2.3 million.
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.